Mar 18, 2015

Another investor attack launched against a pharma patent at the PTAB; and Kyle Bass is not involved

The IPR is over one claim in a patent (no. 7,030,149) related to the glaucoma drug Combigan and has been brought by Ferro Ferrum Capital (FFC), an investment vehicle which was incorporated in Delaware in November and which is majority owned and controlled by Deep Lake Holdings. Neither Bass nor Spangenberg are involved.

Another investor attack launched against a pharma patent at the PTAB; and Kyle Bass is not involved - Blog - Intellectual Asset Management (IAM) - Maximising IP Value for Business
An IPR has been filed against an Allergan patent by an investment firm in a move that will heighten fears in the life sciences industries about the potential damage the PTAB process could do to their IP rights. The latest move comes after two ...